AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 112 min read$PTGX

Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan

Protagonist Therapeutics (PTGX) CEO Dinesh V. Patel exercised 125,000 stock options at $21.58 per share and sold the shares over three days in September 2026 under a 10b5-1 plan. The weighted average sale prices were $145.87, $146.18, and $144.10 per share, respectively, totaling approximately $18.24M in gross proceeds.

Original reporting
stocktitan.net
Published Sep 11, 2026, 1:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PTGX
Neutral
medium confidence
Mentioned
$PTGX
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PTGXNeutralLow
01

Why it matters

The disclosed sale adds temporary selling pressure but is unlikely to trigger a major price move.

02

Market read

Primary insider transaction; modest relevance for traders monitoring PTGX.

03

What to watch

The large spread ($15.5M) could suggest the CEO believes the current price is overvalued, but the pre‑arranged plan mitigates insider‑information concerns.

Relevance 6/10Novelty 7/10Timing: post‑trade (sales occurred Sep 8‑10, article published Sep 11)

Background

Form 4 filing discloses insider transactions; PTGX is a Nasdaq‑listed biotech company.

Company-level read

Ticker impact

$PTGXNeutralMedium confidence
Context

CEO Dinesh V. Patel exercised 125,000 stock options and sold the resulting shares under a Rule 10b5-1 plan, generating a $15.5M pre‑tax spread.

Expected impact

Potential modest short‑term downside as market absorbs the large share sale.

Evidence & confidence

A $15M insider sale by the CEO is material but executed via a pre‑arranged plan, reducing negative implication.

Market effects

Sector

Limited; reflects typical insider activity in biotech sector.

Regional

None beyond the company's own stock.

Global

Low; does not affect broader market indices.

Counterpoint

What could challenge this read

The sale may be purely procedural under the 10b5‑1 plan and not indicative of negative outlook.

Key entities

  • person
    Dinesh V. Patel

    President and CEO of Protagonist Therapeutics who executed the option exercise and sale.

Read at source← All news

Related articles

SEP 8
$PTGXHighAI 8/10

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics (PTGX) announced a $300M share repurchase program, funded by cash reserves and collaboration payments. The program may be executed through open market purchases or other transactions, with timing and amounts dependent on market conditions and other factors. As of June 30, 2026, the company had $849.5M in cash, cash equivalents, and marketable securities, excluding recent milestone payments.

finanznachrichten.de2 min
SEP 6
$PTGXMedAI 8/10

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Protagonist Therapeutics (PTGX) reported a $162.8M profit in Q2 2026, reversing a $34.8M loss from the prior year. The turnaround was driven by milestone payments for two drugs, ICOTYDE and rusfertide, with cash reserves reaching $849.5M. ICOTYDE, approved for psoriasis, triggered a $50M payment and potential $580M more from J&J. Rusfertide, awaiting FDA decision, has already brought in $200M from Takeda, with more milestones pending.

yahoo.com3 min
SEP 4
$PTGXMedAI 8/10

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

FDA approval of MIMRYLO triggered $275M in payments to Protagonist Therapeutics (PTGX), including a $200M opt-out fee and a $75M milestone. PTGX chose royalties over a 50:50 profit split with Takeda (TAK), opting for non-dilutive capital and lower execution risk. PTGX is eligible for up to $875M in additional milestones. The royalty structure ranges from 14% to 29% on worldwide net sales.

insidermonkey.com3 min
SEP 1
$PTGXHighAI 9/10

FDA approves Protagonist and Takeda’s drug for rare blood cancer

FDA approved Protagonist Therapeutics' and Takeda's drug rusfertide (Mimrylo) for polycythemia vera. Mimrylo, a weekly injection, controls red blood cell overproduction. Takeda has not disclosed the price. Analysts forecast peak sales up to $2B. Protagonist's stock has nearly tripled in a year. Mimrylo is Takeda's second of three anticipated drug launches.

bostonglobe.com2 min